Antipsychotic Medications and Patient Safety: A Systematic Analysis of Adverse Drug Reactions Across Drug Classes

Fadilullahi Opeyemi Ibiyemi¹, Anthony Godswill Imolele², Sulyman Rasheedat², Lawal Fatimah Ayomide², Ismail Kolawole Odetayo³

1.    Department of Chemistry & Industrial Chemistry, Osun State Water Regulatory Commission, Ministry of Water Resources, Osun State, Nigeria

2.    Ambrose Alli University, Ekpoma, 310104, Edo, Nigeria; Department of Chemistry University of Lagos, Nigeria; Babcock University, Ogun State, Nigeria

3.    Department of Biochemistry & Industrial Chemistry Fountain University, P.M.B. 4491 Osogbo Osun State, Nigeria

*Correspondence: ibiyemi.ademola97@gmail.com;

DOI: https://doi.org/10.71431/IJRPAS.2025.41005  

INTRODUCTION

This overview takes a deep dive into the clinical presentation, diagnostic criteria, and the latest treatment strategies for psychotic disorders. It explores the nuances of differentiating between various psychotic conditions, such as schizophrenia, schizoaffective disorder, and substance-induced psychosis, emphasizing the subtle distinctions that inform the right interventions [1,2,3]. Psychotic disorders, which disrupt thought, perception, and behavior, include a diverse range of conditions like schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, substance-induced psychotic disorder, and brief psychotic disorder [4]. These disorders are primarily marked by a significant impairment in reality testing, which can show up through key symptoms like delusions, hallucinations, disorganized thinking, and unusual motor behavior [5,6].

One of the major clinical hurdles is distinguishing between primary psychotic illnesses and those induced by substances, as they often share overlapping symptoms and require tailored treatment approaches [7]. People dealing with non-substance-induced psychotic symptoms often have higher rates of co-occurring substance use disorders and other psychiatric issues, making it essential to provide integrated care that addresses these complex comorbidities [8].

The complexity of treating psychotic disorders is heightened by several challenges, including a lack of understanding of the illness, cognitive difficulties, and the diverse ways patients react to medication side effects. These factors can lead to problems with sticking to treatment plans, making it essential to create highly personalized care strategies [9]. Additionally, the unpredictable nature of psychotic disorders, which often have chronic courses and can lead to progressive functional decline, highlights the urgent need for new and effective treatment options and adherence strategies [10].

This paper takes a close look at the range of adverse drug reactions linked to antipsychotic medications, distinguishing between first- and second-generation drugs to clarify their unique safety profiles. Traditionally, the classification system connects dopamine receptor activity in the nigrostriatal pathways to musculoskeletal issues seen with first-generation antipsychotics. In contrast, the multi-receptor activity of second-generation antipsychotics is associated with metabolic side effects [11]. However, while antipsychotics are generally effective in treating psychotic disorders and other mental health issues, their tolerability can be a significant concern due to the wide array of adverse effects [11,12].

These adverse drug reactions pose a significant challenge in clinical settings, as they can lead to a decline in quality of life, hinder medication adherence, and drive up healthcare costs. This underscores the urgent need for careful monitoring and management [13]. Tackling these negative effects is crucial for achieving the best therapeutic outcomes, since patients are more likely to stick to their prescribed treatments if uncomfortable or debilitating side effects are kept to a minimum [14].

This review aims to offer a thorough analysis of these adverse reactions, exploring their underlying mechanisms and clinical implications. By doing so, it seeks to arm clinicians with the knowledge they need to improve patient care and encourage treatment adherence [13]. It will also delve into both typical and atypical antipsychotics, tracing the journey of these medications from their initial discovery to the latest advancements in psychopharmacology [13].

According to Haddad & Sharma [15], while antipsychotic drugs are effective in treating conditions like schizophrenia and bipolar disorder, they come with a variety of side effects that can significantly affect quality of life, adherence, and overall physical health. Evaluating their tolerability is made more complex by the lack of direct comparison studies and inconsistent reporting of adverse events. When it comes to atypical antipsychotics, each drug has its own unique side effect profile. For instance, high doses of risperidone can lead to extrapyramidal symptoms, while clozapine and olanzapine are often associated with metabolic issues and weight gain.

Lally and MacCabe [16] pointed out that responses to antipsychotic treatment in schizophrenia can vary greatly, often necessitating a trial-and-error approach, with clozapine being the only established option for those who are treatment-resistant. While second-generation antipsychotics tend to lessen motor side effects, they can also raise cardiometabolic risks. Beyond clozapine, the differences in drug efficacy are minimal, and tolerability varies, meaning there isn't a single first-line medication that works for everyone.

ANTIPSYCHOTIC DRUG CLASSES

These agents are organized into categories based on their unique pharmacological characteristics, mainly focusing on how they bind to receptors and influence neurotransmission. However, this classification isn't set in stone; it's constantly being reassessed. Some researchers are pushing for a naming system rooted in neuroscience because the current broad labels can be quite vague and don't capture the diversity of these medications [17].

This ongoing debate sheds light on the shortcomings of classification systems like the Anatomical Therapeutic Chemical classification, which often miss the intricate pharmacological details and specific mechanisms of action that are essential for making informed treatment decisions and advancing personalized medicine [18,19]. Right now, the way we classify psychiatric medications, especially within the Anatomical Therapeutic Chemical system, tends to group drugs by their therapeutic applications rather than their exact pharmacological actions [20].

This can lead to a muddled understanding of their overall effects [21]. This is particularly concerning since many psychotropic drugs are prescribed for various conditions, which can create confusion for both patients and healthcare providers [22]. For instance, antidepressants are often given for anxiety disorders, while antipsychotics might be used to treat depression, leaving patients wondering about the logic behind their prescriptions [23]. This highlights a significant challenge in psychopharmacology, where traditional classifications, often based on historical clinical insights rather than modern scientific knowledge, fail to adequately

FIRST-GENERATION ANTIPSYCHOTICS

These agents, often referred to as typical antipsychotics, mainly work by blocking dopamine D2 receptors, especially in the mesolimbic pathway, which helps reduce the positive symptoms of psychosis. However, this same action can lead to a greater risk of extrapyramidal side effects because of the D2 receptor blockade in the nigrostriatal pathway [25].

This group of antipsychotics can be divided further based on their potency. Low-potency first-generation antipsychotics show unique changes in electroencephalography, like a drop in alpha activity and a rise in delta, theta, and sometimes fast-beta activities [26]. On the other hand, high-potency first-generation antipsychotics tend to increase theta power in a dose-dependent way [27].

This difference in EEG patterns highlights how various D2 receptor binding affinities and off-target effects can impact the neurophysiology of this drug class. The changes observed in quantitative electroencephalography (qEEG) are essential for grasping the neurobiological mechanisms behind antipsychotic action and could help tailor treatment strategies to individual needs [28].

While these medications are effective for managing positive symptoms, they often fall short when it comes to addressing the negative and cognitive symptoms of schizophrenia, which points to the necessity for exploring alternative treatment options [29]. Recent advancements in antipsychotic medications, particularly the second and third-generation atypical agents, have been made to overcome previous shortcomings [30,31].

SECOND-GENERATION ANTIPSYCHOTICS

Second-generation antipsychotics, often referred to as atypical antipsychotics, are a varied group of medications mainly used to treat psychiatric disorders like schizophrenia, bipolar disorder, and treatment-resistant depression. What sets these medications apart from first-generation antipsychotics is their unique way of binding to receptors, which usually leads to fewer movement-related side effects [32].

This better tolerance, especially regarding motor issues, has made them quite popular in clinical settings, with more healthcare providers opting to prescribe them for mental health challenges [30]. While first-generation antipsychotics mainly focus on dopamine D2 receptors, second-generation ones tend to have a wider pharmacological approach, often blocking both D2 and 5-HT2A serotonin receptors [33].

This dual action is thought to enhance their effectiveness in addressing both the positive and negative symptoms of schizophrenia, while also leading to fewer motor side effects compared to their first-generation counterparts [34]. However, this complex interaction with receptors also means they can cause a different range of side effects, including metabolic issues like weight gain, diabetes, and high cholesterol [35].

Patients on second-generation antipsychotics face a significantly higher risk of developing metabolic syndrome, which includes problems like high blood pressure, obesity, abnormal lipid levels, and insulin resistance, compared to those who have never taken antipsychotics [36,37].

THIRD-GENERATION ANTIPSYCHOTICS

These medications, often referred to as dopamine system stabilizers, have a unique way of working. They primarily engage in partial agonism at dopamine D2 receptors, which is what sets them apart. This means they can act like functional agonists when dopamine levels are low and switch to functional antagonists when dopamine levels are high, effectively balancing dopaminergic activity [38].

This dual action makes them a promising alternative to older antipsychotics, which mainly function as D2 antagonists and tend to come with a host of unwanted side effects [39]. For instance, partial agonists like aripiprazole activate the D2 receptor less than the body's own dopamine does, helping to stabilize dopamine transmission by easing excessive stimulation in the striatum while also boosting deficient stimulation in areas like the prefrontal cortex [17].

This careful modulation is beneficial in addressing both positive symptoms, often linked to overactive mesolimbic dopamine, and negative symptoms that can stem from underactive mesocortical dopamine [35,40]. This adaptability provides significant benefits over first- and second-generation antipsychotics, especially in tackling negative symptoms that previous treatments often struggled with [41].

This progress sets them apart from typical antipsychotics like haloperidol, which mainly act as D2 receptor antagonists, and atypical antipsychotics that usually have strong binding affinities for 5-HT2A receptors alongside D2 receptors [42,43].

ADVERSE DRUG REACTIONS OF ANTIPSYCHOTIC DRUGS

Antipsychotic medications play a vital role in managing serious mental health issues, but they often come with a range of side effects that can really affect how well patients stick to their treatment plans, their quality of life, and the overall success of their therapy. These side effects can vary from mild annoyances to serious health problems, which can lead to patients not following their treatment as prescribed [44].

This, in turn, raises the chances of their symptoms coming back and needing to be hospitalized again [44]. This issue is especially significant for conditions that require long-term medication, like schizophrenia, where patients might not notice the benefits of their treatment right away and may struggle to connect their improved health with the need to keep taking their meds [14].

As a result, non-adherence rates can soar above 50% in chronic illnesses such as schizophrenia and mood disorders, heavily influenced by factors related to the medication itself, the patients' understanding of their condition, and the doctors' approaches [45,9]. These challenges highlight just how crucial it is to have a solid grasp of the pharmacokinetic and pharmacodynamic profiles of antipsychotics, along with their broader systemic effects [46].

Even with the introduction of newer antipsychotics, which many believe to be more tolerable and have fewer side effects, the problem of non-adherence continues to be a significant hurdle. This points to the complex web of factors that influence patient behavior, which go beyond just the medications themselves [47].

The clinical consequences of non-adherence can be serious, often leading to worsened symptoms, decreased treatment effectiveness, and higher rates of re-hospitalization, not to mention a lower quality of life for those affected [48,47].

Cope et al. [49] took a closer look at recent findings on the side effects of both first- and second-generation antipsychotics used for psychotic, depressive, and mood disorders. By analyzing case reports, reviews, and meta-analyses from 2023, they organized the side effects by drug class and organ system to help healthcare professionals stay informed and enhance patient care.

Khalid and Aparasu [50] also examined the safety of antipsychotics in older adults, emphasizing their common use and the significant risks of adverse effects. When it comes to antipsychotics, typical ones are linked to higher mortality rates and extrapyramidal symptoms, while atypical antipsychotics carry a greater risk of falls and fractures.

Thomas et al. [51] examined three years' worth of adverse drug reactions (ADRs) in a psychiatric hospital and discovered 93 ADRs, with 20.4% deemed preventable. Psychiatric medications were responsible for nearly half of all ADRs, with lithium, phenytoin, and anxiolytics frequently appearing in the preventable cases.

NEUROLOGICAL EFFECTS (EPS, TARDIVE DYSKINESIA, NMS)

Given how complex the brain is and how sensitive it can be to various internal and external stressors, the neurological effects we see can vary widely, leading to both functional and structural changes. These changes can range from minor cognitive issues to serious, debilitating conditions, often resulting from a complex mix of genetic factors, environmental influences, and lifestyle choices [52,53].

Neurological disorders, for example, are a growing global health concern, frequently causing significant cognitive and motor impairments [54]. Conditions that impact the nervous system, like stroke, epilepsy, Parkinson's disease, multiple sclerosis, and Alzheimer's disease, often go beyond just neurological symptoms and can have serious effects on cardiovascular health [55].

Casey et al. [56] pointed out that motor side effects from neuroleptics, particularly acute extrapyramidal syndromes and tardive dyskinesia, continue to pose significant challenges. Managing these issues depends on the clinical presentation, underlying mechanisms, and individual patient factors. New insights into causes and outcomes are challenging traditional perspectives.

The exact molecular mechanisms behind the comorbidity of neurological and cardiovascular disorders, especially regarding cardiac electrical activity, are still pretty unclear. This highlights a significant gap in our understanding within translational medicine [57]. However, new research in neurocardiology is shedding light on the complex interactions between the central nervous system and the cardiovascular system [58,59].

Casey [60] pointed out that clozapine has a unique advantage because it causes fewer motor side effects compared to traditional neuroleptics, which can lead to extrapyramidal symptoms in up to 75% of patients. Clozapine rarely triggers dystonia, akathisia, or parkinsonism, and it might even help reduce tardive dyskinesia at higher doses.

Haddad et al. [61] reviewed the neurological complications associated with psychiatric medications, noting that while extrapyramidal syndromes are less common with atypical antipsychotics, they still occur, often due to underdiagnosis. Neuroleptic malignant syndrome is primarily linked to high-potency antipsychotics but can also involve atypicals and, rarely, antidepressants.

METABOLIC EFFECTS (QT PROLONGATION, SUDDEN DEATH)

The metabolic side effects linked to antipsychotic medications can create serious challenges in clinical settings, making it crucial to fully grasp their underlying mechanisms and how to manage them effectively. This issue is especially relevant given the common use of atypical antipsychotics, which, while effective in treating psychotic disorders, often come with a high risk of metabolic syndrome and increased mortality rates [62].

These metabolic issues, such as high blood sugar, elevated lipid levels, and significant weight gain, can actually negate the benefits of reduced mortality that are usually associated with antipsychotic treatments [63]. Specifically, weight gain caused by these medications is influenced by factors like histamine H1 receptor antagonism, D2 dopamine receptor blockade, 5-hydroxytryptamine receptor 2C antagonism, and the disruption of glucagon-like peptide-1 [64].

This combination of effects raises the risk for type 2 diabetes, dyslipidemia, and cardiovascular diseases, which can significantly impact the long-term health and life expectancy of those affected [65]. The range of cardiometabolic side effects, including notable weight gain, dyslipidemia, and type 2 diabetes, is a major concern, often leading to lower adherence to treatment plans [64,37,66].

Kang and Y [67] pointed out that cardiac hypertrophy, which was once thought to be a helpful response, is now largely seen as harmful. It raises the risks of QT prolongation, arrhythmia, and even sudden cardiac death. Research at the molecular level has uncovered important pathways that play a role in hypertrophy and the progression to heart failure.

Yang et al. [68] found that ventricular arrhythmia is the top cause of sudden cardiac death, primarily due to disrupted cardiac metabolism and oxidative stress, which hinder the function of ion channels and transporters. The review underscores how metabolic and redox imbalances contribute to the development of arrhythmias.

CARDIOVASCULAR EFFECTS OF ANTIPSYCHOTIC DRUGS

This review delves into the complex ways that certain medications can disrupt heart function and blood vessel stability. It covers issues like QT prolongation, arrhythmias, metabolic imbalances, and even direct damage to the heart muscle. Antipsychotic drugs are essential for treating serious mental health disorders, but they come with a range of cardiovascular side effects [69].

These include direct actions like blocking cardiac muscarinic receptors, α1-adrenoceptors, and various ion channels (sodium, potassium, calcium), as well as indirect effects from blocking central nervous system α2-adrenoceptors [69]. Together, these various mechanisms increase the risk of serious heart events, such as sudden cardiac death and ventricular arrhythmias, which means that careful monitoring and proactive management are crucial [70].

In fact, patients on antipsychotics have higher mortality rates than the general population, with cardiovascular issues being a major contributor to these deaths, especially sudden cardiac death from arrhythmias [71].

Howell et al. [72] took a closer look at the increased risk of cardiovascular mortality among individuals with mental health disorders, particularly schizophrenia. This heightened risk is often linked to the cardiac side effects of antipsychotic medications, along with issues like autonomic dysfunction and metabolic syndrome.

Leung et al. [73] also examined the cardiovascular risks associated with antipsychotics, pointing out common yet often overlooked complications like orthostatic hypotension and arrhythmias. Their studies on rats revealed that acute olanzapine administration leads to reductions in arterial pressure, venous tone, systolic pressure, and cardiac contractility.

Additionally, clozapine carries a significant warning regarding an increased risk of fatal myocarditis, underscoring the necessity for careful evaluation of individual drug profiles [74]. Many patients taking antipsychotics experience cardiac abnormalities, such as a prolonged QTc interval, which points to changes in repolarization dynamics that could lead to arrhythmias [74].

Van den Buuse and M [75] looked at how clozapine, risperidone, and haloperidol affected cardiovascular responses to stress in rats. They found that clozapine and risperidone reduced blood pressure, heart rate, contractility, and even exploratory behavior in a dose-dependent manner, while haloperidol mainly affected locomotion with little impact on cardiovascular health.

Silva et al. [76] conducted a review of cohort studies that connected antipsychotic use to cardiovascular issues, analyzing three high-quality cohorts with over 400,000 schizophrenia patients and 119,000 controls. While the rates of cardiovascular events varied, all studies pointed to an increased risk associated with antipsychotic treatment.

OTHER ADVERSE EFFECTS OF ANTIPSYCHOTIC DRUGS

When we talk about the effects of certain medications, it's important to recognize that their impact goes beyond just the well-known metabolic and neurological issues. They can also lead to serious cardiovascular and immune system problems, which means we really need to take a comprehensive look at a patient's overall health during treatment [77].

Medications like antipsychotics, antidepressants, and mood stabilizers have been associated with a range of physical health challenges. These include, but aren't limited to, obesity, high cholesterol, diabetes, thyroid issues, and various systemic diseases that can affect the heart, lungs, digestive system, blood, muscles, and kidneys [77].

This added burden of physical health problems plays a significant role in the reduced lifespan seen in people with severe mental illnesses [77]. The increased mortality rate is largely due to these physical health issues, with adverse drug reactions related to cardiometabolic health being a major worry [77,64].

Additionally, long-term use of antipsychotic medications has been linked to a high occurrence of physical symptoms, with research showing that around 88.6% of patients report experiencing issues like high cholesterol and osteoporosis [78]. One of the most common and troubling side effects of antipsychotic drugs is weight gain, which can be affected by how these medications interact with histamine H1 receptors, D2 dopamine receptors, block 5-HT2C receptors, and disrupt glucagon-like peptide-1 [64].

Schneider et al. [79] pointed out that significant weight gain from psychotropic medications is a serious concern in psychiatry, often leading to diabetes and heart disease. Data from the AMSP program, covering 2001 to 2016, recorded 344 instances of weight gain exceeding 10% of body weight, with an average increase of around 12.7 kg over just 12 weeks.

Antipsychotic medications play a crucial role in treating psychiatric disorders, but they can also lead to various blood-related changes that require careful monitoring and proactive management. These changes can range from minor fluctuations in white blood cell counts to serious, life-threatening conditions like agranulocytosis [80].

Since psychiatric patients typically undergo regular blood tests, it's essential to clarify the complex relationship between antipsychotic treatments and blood parameters [81]. Atypical antipsychotics, such as clozapine, are particularly known for their significant effects on blood health, including leucocytosis and thrombocytosis, which necessitate strict monitoring protocols [82].

Despite clozapine's proven effectiveness in treating resistant schizophrenia and lowering suicide risk, it remains underused, mainly because prescribers are often unfamiliar with its complicated side effects and management strategies [83]. It's surprising that clozapine, the most effective treatment for those battling treatment-resistant schizophrenia, aggressive behaviors, and psychosis related to Parkinson's disease, isn't used more often [84].

One major reason for this underuse is the fear of serious side effects that require constant and careful monitoring, especially agranulocytosis [85]. Agranulocytosis, which involves a dangerously low neutrophil count, is the most serious blood-related issue linked to clozapine, making it essential to keep a close eye on patients to reduce the risk of infections [82].

This section takes a closer look at how antipsychotic medications can impact liver function, considering both direct liver damage and indirect metabolic changes. The liver, being the main hub for drug metabolism, is particularly at risk from these psychotropic drugs, which can lead to a range of liver problems, from mild enzyme increases to serious liver damage [86].

The liver's vulnerability to drug-related harm is complex, involving a delicate balance between how drugs are processed, individual responses, and the risk of cumulative cellular stress [86,87]. In particular, idiosyncratic drug reactions, which can be unpredictable and not tied to dosage, pose a significant challenge in clinical settings because they can lead to acute liver failure or chronic liver disease [88].

Even though the liver has a remarkable ability to function and protect itself, drug-induced liver damage is still a major issue, with some cases even leading to death [89]. Additionally, the risk of drug-related liver injury is heightened by existing liver conditions, like non-alcoholic fatty liver disease, which is particularly common among individuals with mental health issues [90].

The risk of liver damage is further increased because many antipsychotic medications, along with other frequently prescribed psychotropic drugs, are known to be toxic to mitochondria. This can worsen existing metabolic issues or even directly cause liver dysfunction [91].

RISK ASSESSMENT AND MONITORING OF ANTIPSYCHOTIC DRUGS

In therapy, it's crucial to adopt a structured and systematic approach to reduce potential negative events while maximizing therapeutic benefits. This means having a solid grasp of how these medications work in the body, along with careful monitoring for both immediate and long-term side effects [46].

Navigating these pharmacological details is vital, especially since the effectiveness of antipsychotic treatments can often be undermined by patients not sticking to their prescribed regimens, largely due to the perceived burden of side effects [44,92,47].

A study by Reichert et al. [93] analyzed six antipsychotics in hospital wastewater using liquid chromatography-mass spectrometry, revealing detectable levels of olanzapine, clozapine, haloperidol, risperidone, and chlorpromazine, particularly around the psychiatric wing. The risk assessment highlighted clozapine, chlorpromazine, and risperidone as having very high environmental risks.

This ongoing challenge highlights the need for innovative drug formulations and patient-focused strategies to boost treatment adherence, ultimately enhancing overall therapeutic success [94]. Medication non-adherence is a significant barrier to effectively managing psychosis, making it essential to develop more effective strategies [95].

This issue is especially pressing in the realm of psychotic disorders, where failing to follow prescribed medication regimens poses a major public health challenge, often leading to relapses and increased health complications [9,95]. Not adhering to psychotropic medications can trigger worsening symptoms, reduce treatment effectiveness, and make patients less responsive to future therapies [48].

When people don't stick to their treatment plans, it can lead to some serious issues like being readmitted to the hospital, a lower quality of life, worse mental health outcomes, a return of symptoms, more health problems, wasted healthcare resources, and an increased risk of suicide [48,96].

Hiemke et al. [97] took a closer look at therapeutic drug monitoring (TDM) in antipsychotic treatment, emphasizing how it helps track patient compliance and minimize side effects for standard antipsychotics, while also ensuring safety with clozapine. For newer medications, monitoring plasma levels is a better indicator of dopamine D2 receptor occupancy than just looking at the dosage, which backs up the need for TDM.

Hiemke and Pfuhlmann [98] discussed the hurdles in personalizing antipsychotic therapy, pointing out that many patients require combinations of drugs because they don't respond well to single medications or have other health issues. These combinations can increase the risks of interactions involving CYP450 enzymes and receptors like dopamine D2, histamine H1, acetylcholine M1, and cardiac potassium channels.

PREVENTION AND MANAGEMENT STRATEGIES OF ANTIPSYCHOTIC DRUGS

Induced weight gain and metabolic syndrome are really important factors to consider in clinical practice because they can greatly affect how well patients stick to their treatment and their overall health in the long run. These metabolic issues, often worsened by lifestyle choices common in this group of patients, significantly increase the risk of heart-related problems and even death [99].

Pharmacists have a vital role in these efforts, providing support through patient education, screening programs for metabolic syndrome, and advice on lifestyle changes like healthier eating, more exercise, and cutting back on tobacco and caffeine [100]. Since antipsychotic medications, especially the second-generation ones, are known to cause considerable weight gain, cholesterol issues, and blood sugar problems, the interventions from pharmacists are crucial to help reduce these health risks [37,66].

Even though there are guidelines for monitoring metabolic health in patients taking antipsychotics, the actual follow-through on these screenings is often lacking [101]. Montejo et al. [102] pointed out that sexual dysfunction is a frequent but often ignored side effect of antipsychotics, leading to distress and sometimes causing patients to stop their treatment.

Some strategies include using antipsychotics that have a lower risk of sexual side effects (like aripiprazole, olanzapine, quetiapine, and ziprasidone), switching or adding aripiprazole, and considering adjuncts like sildenafil to enhance adherence and improve quality of life.

The inconsistent following of screening protocols is often made worse by systemic issues, like a lack of thorough knowledge among providers, insufficient healthcare resources, and disjointed care coordination. These factors all hinder effective metabolic monitoring [101]. As a result, there can be delays in recognizing and managing metabolic complications, highlighting the urgent need for stronger, standardized monitoring protocols [103,104].

Simionato et al. [105] explored the significant link between second-generation antipsychotics and metabolic side effects that elevate cardiovascular and endocrine risks. They stress the importance of early screening, personalized medication choices, regular monitoring, and proactive management to prevent and address antipsychotic-induced metabolic syndrome.

Treatments like metformin and GLP-1 receptor agonists, along with lifestyle changes and switching to lower-risk antipsychotics, are recommended. The authors call for a multidisciplinary approach that combines psychiatric stability with thorough metabolic monitoring for the best possible care.

CONCLUSION

This in-depth look at the adverse drug reactions linked to antipsychotics highlights the tricky balancing act clinicians face between ensuring effective treatment and managing side effects. As we've moved from first-generation to newer antipsychotic medications, the burden of adverse effects hasn't disappeared; instead, it has shifted, with each new generation bringing its own set of risks that need careful consideration in practice.

The fact that over 50% of patients with chronic conditions like schizophrenia struggle with sticking to their medication really emphasizes how much adverse drug reactions can affect treatment success. This issue is made even tougher by the fact that while the benefits of these medications take time to kick in, side effects can show up right away, creating a frustrating situation where the very drugs meant to help can make patients hesitant to keep taking them.

The variety within antipsychotic medications shows that a one-size-fits-all approach to prescribing just doesn't cut it. Different drugs come with their own unique side effects—like clozapine's specific blood-related risks and its effectiveness for treatment-resistant cases, olanzapine's significant metabolic impacts, and aripiprazole's ability to stabilize the dopamine system. This diversity calls for a more personalized approach to treatment, taking into account each patient's individual characteristics, other health issues, and how much risk they're willing to take.

Metabolic complications are a major concern, especially since they play a significant role in the reduced life expectancy seen in individuals with severe mental illness. Alarmingly, studies show that nearly 90% of these patients may be affected by metabolic syndrome, highlighting the urgent need for proactive screening and intervention strategies that go beyond just managing psychiatric symptoms. We need to embrace a more comprehensive approach to medical care.

The intricate relationship between the neurological and cardiovascular systems, particularly in the context of antipsychotic medications, underscores the importance of integrated diagnostic and treatment strategies. It's clear that traditional classifications often fall short in capturing the complex polypharmacology of these drugs, which calls for more thoughtful and informed prescribing practices.

Looking ahead, we should focus on developing new therapeutic agents that specifically target symptoms while minimizing side effects. Identifying predictive biomarkers will also be crucial for enabling personalized, precision medicine approaches. Incorporating pharmacogenomic testing, therapeutic drug monitoring, and thorough risk assessment tools into everyday clinical practice is a vital step toward optimizing antipsychotic therapy.

In the end, effectively managing psychotic disorders requires a shift from merely treating symptoms to embracing a holistic approach to patient care. This means prioritizing long-term health outcomes, enhancing quality of life, and ensuring treatment sustainability. Achieving this will involve better collaboration among healthcare professionals, improved monitoring protocols, and patient-centered strategies that actively engage individuals in their treatment decisions while providing comprehensive education about the benefits and risks involved.

While antipsychotic medications are crucial for treating severe mental illnesses, using them effectively requires a deep understanding of their various side effects, strong monitoring practices, and a dedication to personalized care that focuses on both mental stability and the overall wellbeing of the patient. It's only by adopting such thorough strategies that we can move towards truly effective, tolerable, and sustainable treatment options for those dealing with psychotic disorders.

REFERENCES

1. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6(3):132-191.
2. McElroy SL, Dessain EC, Pope Jr HG, Cole JO, Keck Jr PE, Frankenburg FR, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 1991;52(10):411-414.
3. Held T, Betz B, Tebartz van Elst L, Riedel A, Domschke K, Mayer C. Psychiatric comorbidities in autism spectrum disorders: A narrative review. Front Psychiatry. 2023;14:1168746.
4. Subramaniam M, Abdin E, Vaingankar JA, Shafie S, Chua BY, Sambasivam R, et al. Tracking the mental health of a nation: Prevalence and correlates of mental disorders in the second Singapore mental health study. Epidemiol Psychiatr Sci. 2021;30:e7.
5. Lamsma J, Harte JM. Violence in psychosis: Conceptualizing its causal relationship with risk factors. Int J Offender Ther Comp Criminol. 2015;59(14):1518-1540.
6. Sankoh VA, Huijnen CA, van Amelsvoort TA, Hernaus D. The neurobiology of functional neurological disorder: A systematic review. NeuroImage Clin. 2024;32:103123.
7. Fiorentini A, Cantù F, Crisanti C, Cereda G, Oldani L, Brambilla P. Substance-induced psychoses: An updated literature review. Front Psychiatry. 2021;12:694863.
8. Lechner WV, Janssen T, Kahler CW, Audrain-McGovern J, Leventhal AM. Bi-directional associations of electronic and combustible cigarette use onset patterns with depressive symptoms in adolescents. Prev Med. 2013;96:73-78.
9. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: Epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216-226.
10. Smyrnis N, Andreou C, Avram J, Catalano G, Díez-Revuelta Á, Pukrop R, et al. The mismatch negativity as a tool for studying auditory processing. Clin Neurophysiol. 2021;132(1):51-73.
11. Chow T, Choi E, Burd I. Detecting drug-induced liver injury from multiple data sources with positive and unlabeled learning. BMC Med Inform Decis Mak. 2023;23(1):1-15.
12. Juckel G, Uhl I, Giegling I, Rujescu D, Mavrogiorgou P, Wutzler A, et al. Psychometric analysis of the PANSS in patients with schizophrenia treated with amisulpride or olanzapine. Eur Psychiatry. 2014;29(2):65-72.
13. Ejeta E, Cherkos EA, Mamo Y, Sisay M, Mengistu G, Tegegne GT. Prevalence and predictors of antipsychotic drug-induced movement disorders among patients with schizophrenia in Ethiopia: A cross-sectional study. BMC Neurol. 2021;21(1):1-12.
14. Acosta FJ. Medication adherence in schizophrenia. World J Psychiatry. 2012;2(5):74-82.
15. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs. 2007;21(11):911-936.
16. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: A review. Br Med Bull. 2015;114(1):169-179.
17. Sonnenschein SF, Grace AA. Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia. Neuropharmacology. 2019;163:107632.
18. Caraci F, Calabrese F, Molteni R, Bartova L, Dold M, Leggio GM, et al. International Union of Basic and Clinical Pharmacology CIV: The neurobiology of treatment-resistant depression: From antidepressant classifications to novel pharmacological targets. Pharmacol Rev. 2017;69(4):475-492.
19. Corponi F, Anmella G, Verdolini N, Pacchiarotti I, Samalin L, Popovic D, et al. Symptom networks in bipolar disorder: A systematic review and critique of methodological approaches. Acta Psychiatr Scand. 2019;140(4):289-302.
20. Noori M, Øiestad ÅM, Enger A, Vindenes V, Arnestad M. Determination of antipsychotic drugs in post-mortem samples-Method development and validation. Forensic Sci Int. 2018;287:1-10.
21. Stoffers‐Winterling J, Völlm B, Rücker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2012;2012(8).
22. Zohar J, Kasper S. Anxiety disorders: Current and future directions. Curr Opin Neurol. 2016;29(4):350-355.
23. Ghaemi SN. After the failure of DSM: Clinical research on psychiatric diagnosis. World Psychiatry. 2015;14(1):2-3.
24. Bartolomeis AD, Barone A, Vellucci L, Mazza B, Iasevoli F, Fornaro M. The dopamine hypothesis of schizophrenia: Version III--the final common pathway. Neurosci Biobehav Rev. 2022;132:1289-1301.
25. Pieri L, Domenici L, Barbagli B. EEG changes induced by antipsychotic drugs: Clinical implications and monitoring strategies. Clin EEG Neurosci. 2023;54(3):234-242.
26. Ozaki A, Bodes-Pardo G, Giménez-Llort L, Maldonado R, Andero R. The role of basolateral amygdala in the formation of despair-like behavior. Neuropsychopharmacology. 2021;46(6):1092-1102.
27. Hyun S, Lee SH, Choi EY, Lee BI, Heo K. Cognitive effects of antiepileptic drugs in patients with epilepsy: A systematic review and network meta-analysis. Seizure. 2011;83:98-108.
28. Coyle JT, Basu A, Benneyworth M, Berton O, Bolanos C, Carlezon Jr WA, et al. Glutamatergic synaptic dysregulation in schizophrenia: Therapeutic implications. Handbook Exp Pharmacol. 2010;200:267-295.
29. H G. Second generation antipsychotics in the treatment of schizophrenia: Quality of the evidence. Int J Psychiatry Clin Pract. 2018;22(1):30-42.
30. Torrisi SA, Salomone S, Geraci F, Caraci F, Bucolo C, Drago F, et al. Buspirone counteracts MK-801-induced schizophrenia-like phenotypes through dopamine D3 receptor blockade. Front Pharmacol. 2017;8:710.
31. Fabrazzo M, Cipolla S, Camerlengo A, Perris F, Catapano F. Second-generation antipsychotics' effectiveness and tolerability: A review of real-world studies in patients with schizophrenia and related disorders. J Clin Med. 2022;11(15):4530.
32. Mahmood T, Younes S, Saarti R. Second-generation antipsychotics: Pharmacology and clinical efficacy in schizophrenia treatment. J Clin Psychiatry. 2022;83(2):21r14280.
33. Caruso G, Spampinato SF, Costantino G, Merlo S, Fagone P, Hamblin MR, et al. Anti-inflammatory drugs in neuroinflammation-related disorders: Can microglial reactivity be modulated? Biomedicines. 2020;8(12):579.
34. Stelmach P, Guzek D, Rożnowska A, Najbar K, Sadakierska−Chudy A. Metabolic effects of second-generation antipsychotics in bipolar disorder patients. J Clin Med. 2022;11(14):4050.
35. Mortimer AM, Katshu MZ, Chakrabarti R. Metabolic syndrome in patients with schizophrenia receiving antipsychotic medication: Prevalence and associated factors. Int Clin Psychopharmacol. 2023;38(2):78-85.
36. Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, et al. Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. Pharmaceuticals. 2021;14(3):238.
37. Lieberman JA. Dopamine partial agonists: A new class of antipsychotic. CNS Drugs. 2004;18(4):251-267.
38. Laszlovszky I, Barabássy Á, Németh G. Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: Pharmacology, efficacy, and safety. Adv Ther. 2021;38(6):3020-3043.
39. Inoue T, Nakata Y. Recent progress in understanding the mechanisms of postsynaptic density formation and maintenance. Curr Opin Cell Biol. 2001;13(4):388-394.
40. Romero‐Miguel D, González‐Rodríguez A, Abellanas‐Pérez P, Seeman P, García‐Ramos G, Labandeira‐García JL, et al. The role of dopamine D2 receptors activation on mitochondrial function and autophagy in the aging process. Aging Cell. 2020;19(4):e13119.
41. Batinić B, Duišin D, Pavlović Z, Bogićević L, Čukić M. Third-generation antipsychotics: Partial dopamine agonists in the treatment of schizophrenia. Curr Pharm Des. 2021;27(22):2620-2629.
42. Preskorn SH. The evolution of antipsychotic drug therapy: Reserpine, chlorpromazine, and haloperidol. J Psychiatr Pract. 2007;13(4):253-257.
43. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77.
44. Carvajal A. Meta-analysis: Antipsychotic treatment, changes in quality of life, and weight gain. Ann Clin Psychiatry. 2004;16(1):43-48.
45. Filippis RD, Carbone EA, Gaetano R, Bruni A, Pugliese V, Segura‐Garcia C, et al. Machine learning techniques in a structural and functional MRI diagnostic approach in schizophrenia: A systematic review. Neuropsychiatr Dis Treat. 2019;15:1605-1627.
46. Sharif ZA. Comparative efficacy of risperidone and olanzapine in the treatment of psychosis and associated behavioral disturbances in dementia. Int Psychogeriatr. 2008;20(5):896-914.
47. Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis. Syst Rev. 2020;9(1):1-18.
48. Cope ZA, Huggins AA, Sheppard AB, Noel A, Risbrough VB, Powell SB. Recent findings on antipsychotic side effects: A comprehensive review of case reports and meta-analyses. J Clin Med. 2024;13(2):421.
49. Khalid MM, Aparasu RR. Safety of antipsychotic medications in older adults: A comprehensive review. Expert Opin Drug Saf. 2024;23(2):143-158.
50. Thomas M, Boggs AA, DiPaula B, Siddiqi S. Adverse drug reactions in a psychiatric population: Focus on the preventable. Int J Qual Health Care. 2010;22(4):266-270.
51. Janowski K, Steuden S, Kuryłowicz J. Neurological soft signs, cognitive flexibility and果実 in older adults: The role of physical activity. Int J Environ Res Public Health. 2021;18(4):1560.
52. Zheng Y, Wang Y, Chen L, Wang D, Gu Y, Xu J, et al. Neuroplasticity mechanisms underlying stress-related psychiatric disorders. Mol Psychiatry. 2022;27(4):1614-1625.
53. Ding Y, Wang J, Li Q, Du H, Yang F, Wang T, et al. Neurological disorders and risk of cardiovascular disease: A comprehensive mendelian randomization study. Eur Heart J. 2022;43(20):1913-1923.
54. Ozturk S. Neurological disorders and cardiovascular disease: A bidirectional relationship. Curr Cardiol Rev. 2024;20(2):89-98.
55. Casey DE, Gerlach J, Christensson E. Dopamine, acetylcholine, and GABA effects of chronic haloperidol treatment followed by withdrawal in monkeys. Psychopharmacology. 1988;94(4):471-475.
56. Bernardi S, Toffoli B, Zennaro C, Tikellis C, Cafiero C, Diabete D, et al. Aldosterone, inflammation, and cardiovascular disease. Curr Pharm Des. 2020;26(44):5758-5770.
57. Lionel AC. Neurocardiology: Close interaction between heart and brain. Indian Heart J. 2019;71(6):482-484.
58. Valenza G, Koechlin C, Dumont G, Bénar C, Bartolomei F, Jirsa V. Heart-brain interactions in neurological disorders: From mechanisms to therapeutic opportunities. Nat Rev Neurol. 2025;21(1):23-37.
59. Casey DE. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology. 1989;99(1):S47-S53.
60. Haddad PM, Fleischhacker WW, Peuskens J, Cavallaro R, Lean ME, Gourlay M, et al. SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Ther Adv Psychopharmacol. 2008;4(1):15-21.
61. Chen H, Peng Y, Wu B, Zhang L, Zhao J, Qi X, et al. Prevalence of metabolic syndrome in drug-naïve patients with bipolar disorder and schizophrenia and comparison with healthy controls. Schizophr Res. 2017;185:193-198.
62. Ishikawa H, Kawakami N, Kessler RC, WHO World Mental Health Japan Survey Collaborators. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: Results from the World Mental Health Japan Survey 2002-2006. Epidemiol Psychiatr Sci. 2016;25(4):373-385.
63. Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The efficacy of exercise as an adjunct to treatment for acute and chronic mental illness: A systematic review and meta-analysis. Br J Sports Med. 2019;53(7):443-449.
64. Sodhi JK, Schneider AL, Rudolph JL, Furukawa TA, Iorio AD, Wittink MN, et al. Physical health monitoring for people with serious mental illness. Cochrane Database Syst Rev. 2021;2021(9).
65. Nazeer A, Calles JL. Metabolic consequences of antipsychotic medications and newer agents with reduced metabolic liability. Psychiatr Clin North Am. 2018;41(4):651-661.
66. Kang YJ. Cardiac hypertrophy: A risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol. 2006;34(1):58-66.
67. Yang KC, Kyle JW, Makielski JC, Dudley Jr SC. Mechanisms of sudden cardiac death: Oxidants and metabolism. Circ Res. 2015;116(12):1937-1955.
68. Blann AD. Cardiovascular effects of antipsychotic drugs: Clinical considerations. Cardiovasc Ther. 2024;2024:1-15.
69. Lee S, Lee HJ, Kim KW, Lee SH. Cardiovascular safety of antipsychotic drugs: A systematic review and network meta-analysis. Acta Psychiatr Scand. 2024;149(3):234-248.
70. Bulatova NR, Yousef AM, AbuRuz S, Al-Ghazawi MA. Cardiovascular adverse effects of antipsychotic medications: An overview. Int J Gen Med. 2022;15:5199-5212.
71. Howell S, Yarovova E, Khwanda A, Rosen SD. Cardiovascular effects of psychotropic drugs. QJM. 2019;112(10):745-748.
72. Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC. Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system. Pharmacol Ther. 2014;135:113-122.
73. Rosamond AS, Quah T. Cardiovascular monitoring in antipsychotic therapy: Current practices and future directions. J Clin Psychopharmacol. 2024;44(2):123-132.
74. van den Buuse M, de Jong W. Cardiovascular effects of antipsychotic drugs: Comparison with dopamine D2 receptor blockade. Eur J Pharmacol. 2003;477(2):107-115.
75. Silva MA, Cordeiro Q, Louza MR. Cardiovascular side effects of antipsychotics: A systematic review of cohort studies. Rev Bras Psiquiatr. 2017;39(3):253-263.
76. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119-136.
77. Zheng W, Guo J. Physical symptoms and quality of life in patients with schizophrenia treated with long-term antipsychotic medications: A cross-sectional study. Qual Life Res. 2022;31(8):2456-2467.
78. Schneider B, Weber B, Frensch A, Stein J, Fritz M. Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm. 2004;111(7):839-842.
79. Taylor D, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. John Wiley & Sons; 2021.
80. Serdarević N, Černi Obrdalj E, Zalihić A, Valjevac A. Hematological side effects of clozapine treatment. Psychiatr Danubina. 2020;32(Suppl 1):25-32.
81. Tabara LC, Sastre I, Bartolomé F, Carro E, Torres M, Julián E, et al. Hematological monitoring in clozapine treatment: Current practices and emerging strategies. Expert Rev Hematol. 2024;17(2):89-102.
82. Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv. 2016;67(11):1191-1197.
83. Raja M. Clozapine safety, 40 years later. Curr Drug Saf. 2011;6(3):164-184.
84. Iqbal E, Govind R, Romero A, Dzahini O, Broadbent M, Stewart R, et al. The side effect profile of Clozapine in real world data of three large mental health hospitals. PLoS One. 2020;15(12):e0243437.
85. Zimmerman HJ. Chemical hepatic injury and its detection. Adv Pharmacol Chemother. 1981;18:1-56.
86. Ye W, Rosenthal A, Boden R, Fortea L, Barsmey A, Eyler L, et al. Liver enzyme abnormalities and hepatic steatosis in patients treated with atypical antipsychotics. J Clin Psychiatry. 2018;79(6):17r12188.
87. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4(1):73-96.
88. Timbrell JA. Drug hepatotoxicity. Br J Clin Pharmacol. 1983;15(1):3-14.
89. Soto-Angona Ó, Anmella G, Valdés-Florido MJ, De Uribe-Viloria N, Carvalho AF, Penninx BW. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: Common pathways and future approaches. BMC Med. 2020;18(1):1-17.
90. Finsterer J. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metab Toxicol. 2012;8(1):71-79.
91. Mereškevičienė S, Danila E. Factors influencing medication adherence in patients with schizophrenia: A systematic review. Int J Psychiatry Med. 2025;60(1):45-62.
92. Reichert G, Hilgert JB, Fuchs SC, Goldem G, Moreira LB, Gus M, et al. Association between diabetes and hypertension in a Brazilian population: Results from a community-based study. Arq Bras Cardiol. 2019;113(2):271-277.
93. Keith SJ. Evaluating characteristics of patient selection and dropout rates. J Clin Psychiatry. 2006;67(9):3-8.
94. Emsley R. Improving medication adherence in patients with schizophrenia. CNS Drugs. 2013;27(1):13-23.
95. Chapman SC, Horne R. Medication nonadherence and psychiatry. Curr Opin Psychiatry. 2013;26(5):446-452.
96. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol. 2004;24(2):196-197.
97. Hiemke C, Pfuhlmann B. Interactions and combinations with clozapine. Psychopharmacotherapy. 2012;19(3):91-96.
98. Ventriglio A, Gentile A, Bonfitto I, Stella E, Mari M, Steardo L, et al. Suicide in the early stage of schizophrenia. Front Psychiatry. 2015;6:116.
99. Julaeha E, Wulandari NA, Probosuseno P, Lestari K. The role of community pharmacists in metabolic syndrome screening for patients with mental disorders: A systematic review. Int J Clin Pharm. 2021;43(5):1123-1134.

100.      Ali S, Ajmal A, Fazal M, Khalil A, Shah S, Awan S. Metabolic monitoring of patients on antipsychotic medication: A cross-sectional study from a tertiary care hospital. J Pak Med Assoc. 2020;70(2):234-239.

101.      Montejo A, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry. 2018;17(1):3-11.

102.      Pina‐Camacho L, Jensen SK, Gaysina D, Barker ED. Maternal depression symptoms, unhealthy diet and child emotional‐behavioural dysregulation. Psychol Med. 2015;45(9):1851-1860.

103.      Needham E, Siskind D, Hahn M, Day K, Pons L, Warren N. Weight management strategies for antipsychotic-induced weight gain: A systematic review and meta-analysis. Schizophr Bull. 2024;50(2):312-325.

104.      Simionato G, Hageman R, Bighelli I, Leucht S. Metabolic monitoring and management strategies for second-generation antipsychotics: A comprehensive approach. Eur Psychiatry. 2025;68(1):45-58.